Serum anti-myomegalin antibodies in patients with esophageal squamous cell carcinoma

  • Authors:
    • Hideaki Shimada
    • Mari Kuboshima
    • Tooru Shiratori
    • Yoshihiro Nabeya
    • Atsushi Takeuchi
    • Hiroaki Takagi
    • Fumio Nomura
    • Masaki Takiguchi
    • Takenori Ochiai
    • Takaki Hiwasa
  • View Affiliations

  • Published online on: January 1, 2007     https://doi.org/10.3892/ijo.30.1.97
  • Pages: 97-103
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

In order to identify new serum markers of esophageal squamous cell carcinoma (SCC), we performed serological identification of antigens by recombinant cDNA expression cloning (SEREX). E. coli was transformed with a λZAPII phage cDNA library prepared from mRNA of an esophageal cancer cell line (T.Tn), and IPTG-induced cDNA products were screened for interaction with antibodies in allogeneic sera of patients with esophageal SCC. We identified myomegalin (MMGL, phosphodiesterase 4D interacting protein/PDE4DIP) as a new SEREX antigen for esophageal SCC. Western blot analysis revealed that serum anti-myomegalin antibodies (s-MMGL-Abs) were present in 43 (47%) of 91 patients, but in only one (2.2%) of 45 healthy controls. Of the 21 patients with stage I disease, 8 (38%) were sero-positive. The positive rate of s-MMGL-Abs was greater than those of other conventional tumor markers. Reverse transcription-PCR analysis suggested that alternative splicing from myomegalin variant 1 to variant 5 may explain, in part, the development of s-MMGL-Abs. Although the presence of s-MMGL-Abs was not related to any clinicopathological features of the patients, multivariate analysis indicated that the presence of s-MMGL-Abs was significantly associated with a favorable prognosis. Consequently, s-MMGL-Abs may be a useful tumor marker to diagnose and establish a prognosis in patients with esophageal SCC.

Related Articles

Journal Cover

January 2007
Volume 30 Issue 1

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Shimada H, Kuboshima M, Shiratori T, Nabeya Y, Takeuchi A, Takagi H, Nomura F, Takiguchi M, Ochiai T, Hiwasa T, Hiwasa T, et al: Serum anti-myomegalin antibodies in patients with esophageal squamous cell carcinoma. Int J Oncol 30: 97-103, 2007
APA
Shimada, H., Kuboshima, M., Shiratori, T., Nabeya, Y., Takeuchi, A., Takagi, H. ... Hiwasa, T. (2007). Serum anti-myomegalin antibodies in patients with esophageal squamous cell carcinoma. International Journal of Oncology, 30, 97-103. https://doi.org/10.3892/ijo.30.1.97
MLA
Shimada, H., Kuboshima, M., Shiratori, T., Nabeya, Y., Takeuchi, A., Takagi, H., Nomura, F., Takiguchi, M., Ochiai, T., Hiwasa, T."Serum anti-myomegalin antibodies in patients with esophageal squamous cell carcinoma". International Journal of Oncology 30.1 (2007): 97-103.
Chicago
Shimada, H., Kuboshima, M., Shiratori, T., Nabeya, Y., Takeuchi, A., Takagi, H., Nomura, F., Takiguchi, M., Ochiai, T., Hiwasa, T."Serum anti-myomegalin antibodies in patients with esophageal squamous cell carcinoma". International Journal of Oncology 30, no. 1 (2007): 97-103. https://doi.org/10.3892/ijo.30.1.97